PF-Atlas › Clinical Trials › NCT03727451

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

iNO · Phase 2

Registry ID
NCT03727451
Phase
Phase 2
Status
Completed
Drug / intervention
iNO
Sponsor
Bellerophon
Start
2019-01-30
Enrollment
17
Locations
6

About this trial

A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term extension study

View NCT03727451 on ClinicalTrials.gov →

Explore related

Mocetinostat — Treatment profileAll iNO trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03727451 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.